Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Martin Shkreli attributes arrest to drug-price hikes - WSJ

Published 21/12/2015, 06:53
© Reuters. Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn in New York
TWTR
-
TVTX
-

(Reuters) - Martin Shkreli, the pharmaceutical entrepreneur facing U.S. charges of securities fraud, has said he had been the target of legal authorities for his much-criticized drug-price hikes and his over-the-top public persona, the Wall Street Journal reported.

Shkreli, who was arrested on Thursday and released soon after on a $5 million bond, has been charged for engaging in what U.S. prosecutors said was a Ponzi-like scheme at his former hedge fund MSMB Capital Management and Retrophin Inc (O:RTRX), a company he headed before he took the helm of Turing Pharmaceuticals Inc. The maximum sentence for the top count is 20 years in prison.

Earlier this year, after buying a 60-year-old drug called Daraprim, Turing raised the price overnight to $750 (£503) a tablet from $13.50 (£9.05). The increase propelled Shkreli to the media spotlight: Presidential candidate Hillary Clinton pilloried him for gouging, and he was pulled into congressional drug pricing investigations.

The government charges do not include activities at privately held Turing.

"'Trying to find anything we could to stop him' was the attitude of the government," Shkreli told the Journal in an interview, saying he was arrested because of a social experiment and teasing people over the Internet, and called the arrest unjust. (http://on.wsj.com/1kbByJV)

According to the Journal, a Federal Bureau of Investigation official earlier said Shkreli pursued "a securities fraud trifecta of lies, deceit and greed."

While being unapologetic about the price of Daraprim, Shkreli added in the interview that Turing, from which he resigned as chief executive after the arrest, might change its approach.

Turing, on Friday, replaced Shkreli with Ron Tilles, who has been chairman of the company since its launch. They co-founded the pharmaceutical company, Retrophin.

Reuters could not independently reach the FBI and Brooklyn U.S. Attorney's office for comment outside regular U.S. business hours.

© Reuters. Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn in New York

In a separate incident, on Sunday, Martin Shkreli had lost control of his Twitter (N:TWTR) account to hackers, hours after he took to Twitter to plead his innocence, his spokesman said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.